Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN OTIC versus XTORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN OTIC versus XTORO.
FLOXIN OTIC vs XTORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
XTORO is a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), leading to reduced angiogenesis and tumor vascularization.
Instill 5 drops (0.5 mL) into affected ear(s) twice daily for 10-14 days; for acute otitis externa, may use 5 drops twice daily for 7 days.
100 mg orally once daily.
None Documented
None Documented
6-8 hours in adults with normal renal function; prolonged to 30-50 hours in severe renal impairment (CrCl <20 mL/min).
Terminal t1/2 12 hours; in renal impairment (CrCl <30 mL/min) extends to 24 hours; requires dose adjustment
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (70-80%); non-renal elimination (hepatic metabolism and biliary secretion) accounts for 20-30%.
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; 10% other
Category C
Category C
Otic Antibiotic
Otic Antibiotic